Bonn International Graduate School of Drug Sciences
Picture Sources: Dr. Thomas Mauersberg (picture 1 & 7), Frank Homann (pictures 2 & 6), Barbara Frommann (pictures 3 - 5)
The BIGS DrugS seeks talented biomedical scientists from around the world. We encourage outstanding applicants with a university degree (master, diploma or state exam) in life sciences, medical sciences, pharmacy or related fields to apply for admission to the BIGS DrugS PhD program. Find out more here.
Welcome to the BIGS DrugS homepage
BIGS DrugS is a structured graduate program focusing on pharmacological and pharmaceutical sciences. BIGS DrugS scientists are dedicated to basic and applied research related to novel drugs and therapies. BIGS DrugS seeks talented biomedical scientists to join the interdisciplinary program. The training program is in English and covers lectures, workshops and scientific talks. Explore our webpage for more information on the BIGS DrugS graduate program.
Publications
BIGS DrugS students and principal investigators have recently successfully published their reserach results. Congratulations! Find more publications here.
Hamedani NS, Rühl H, Zimmermann JJ, Heiseler T, Oldenburg J, Mayer G, Pötzsch B, Müller J. In Vitro Evaluation of Aptamer-Based Reversible Inhibition of Anticoagulant Activated Protein C as a Novel Supportive Hemostatic Approach. Nucleic Acid Ther. 2016 Dec;26(6):355-362.
Brunschweiger A, Koch P, Schlenk M, Rafehi M, Radjainia H, Küppers P, Hinz S, Pineda F, Wiese M, Hockemeyer J, Heer J, Denonne F, Müller CE. 8-Substituted 1,3-dimethyltetrahydropyrazino[2,1-f]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitors. Bioorg Med Chem. 2016 Nov 1;24(21):5462-5480. doi: 10.1016/j.bmc.2016.09.003.
López-Cruz L, Dan-Miguel N, Bayarri P, Baqi Y, Müller CE, Salamone JD, Correa M. Ethanol and caffeine effects on social interaction and recognition in mice; involvement of adenosine A2A and A1 Receptors. Frontiers Behav. Neurosci. 2016 Nov, 10, 1-15.
Wißbrock A, Kühl T, Silbermann K, Becker AJ, Ohlenschläger O, Imhof D. Synthesis and evaluation of Abeta-derived and Abeta-independent enhancers of the peroxidase-like activity of heme. J. Med. Chem., 2016 Nov, doi: 10.1021/acs.jmedchem.6b01432.
Burbiel JC, Ghattas W, Küppers P, Köse M, Lacher S, Herzner AM, Kombu RS, Akkinepally RR, Hockemeyer J, Müller CE. 2-Amino[1,2,4]triazolo[1,5-c]quinazolines and derived novel heterocycles: Synthesis and structure-activity relationships of potent adenosine receptor antagonists. ChemMedChem 2016 Oct, 11, 2272-2286.
Goradia N, Wißbrock A, Wiedemann C, Bordusa F, Ramachandran R, Imhof D, Ohlenschläger O. 1H, 13C, and 15N resonance assignments for the pro-inflammatory cytokine interleukin-36α. Biomolecular NMR assignments. 2016 Oct, 10, 329-333.
Joerger M, von Pawel J, Kraff S, Fischer JR, Eberhardt W, Gauler TC, Mueller L, Reinmuth N, Reck M, Kimmich M, Mayer F, Kopp HG, Behringer DM, Ko YD, Hilger RA, Roessler M, Kloft C, Henrich A, Moritz B, Miller MC, Salamone SJ, Jaehde U. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2016 Oct; 27:1895-1902
Mir Mohseni M, Höver T, Barra L, Kaiser M, Dorrestein PC, Dickschat JS, Schäberle TF. Discovery of a Mosaic-Like Biosynthetic Assembly Line with a Decarboxylative Off-Loading Mechanism through a Combination of Genome Mining and Imaging. Angew Chem Int Ed Engl. 2016 Oct 17;55(43):13611-13614. doi: 10.1002/anie.201606655.
Rafehi M, Burbiel JC, Attah IY, Abdelrahman A, Müller CE. Synthesis, characterization, and in vitro evaluation of the selective P2Y2 receptor antagonist AR-C118925. Purinergic Signal. 2016 Oct 20. [Epub ahead of print]
Fiene A, Baqi Y, Malik EM, Newton P, Li W, Lee SY, Hartland EL, Müller CE. Inhibitors for the bacterial Ectonucleotidase Lp1NTPDase from Legionella pneumophila. Bioorg. Med. Chem. 2016 Sep, 24, 4363-4371.
